Decibel Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Laurence Reid

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	44.5%
Dienstverband CEO	3.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

Analyse CEO-vergoeding

Hoe is Laurence Reid's beloning veranderd ten opzichte van Decibel Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

Compensatie versus markt: De totale vergoeding ($USD 1.23M ) Laurence } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Laurence is gestegen terwijl het bedrijf verliesgevend is.

CEO

Laurence Reid (59 yo)

3.8yrs

Tenure

US$1,232,276

Compensatie

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Laurence Reid	President & CEO	3.8yrs	US$1.23m	geen gegevens
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Murphy	Interim CFO	less than a year	geen gegevens	geen gegevens
Elaine Cope	Vice President of Operations	2.1yrs	geen gegevens	geen gegevens
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	geen gegevens	geen gegevens
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DBTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens
Alan Cheng	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Ginty	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Greenberg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dwight Bergles	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DBTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Decibel Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd